RxDoctor Payments Data

Kavita Rao, MD

Internal Medicine · Saint Petersburg, FLNPI 1083684153

Payments from drug & device makers

$3,770in general payments, 2019–2025

Across 203 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$876
  • GSK$407
  • Novo Nordisk$323
  • Johnson & Johnson$217
  • Pfizer$165
  • plus $689 from 17 others

What the payments were for

  • Food & beverage$3,770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,770 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$251,930
Medicare patients
557
Services billed
2,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$63,257
TrulicityDulaglutide28$55,471
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$55,306
OzempicSemaglutide18$36,738
JanuviaSitagliptin Phosphate31$28,304
XareltoRivaroxaban20$25,039
LinzessLinaclotide26$22,883
FarxigaDapagliflozin Propanediol13$19,917
VraylarCariprazine Hcl15$19,598
Advair HfaFluticasone Propion/Salmeterol21$11,381
JardianceEmpagliflozin13$10,116
SymbicortBudesonide/Formoterol Fumarate16$9,627
Humulin R U-500 KwikpenInsulin Regular, Human14$7,725
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,558
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$63,25753 claims
GSKTrelegy Ellipta$407$55,30639 claims
AbbVieLinzess, Vraylar$1,095$42,48141 claims
Novo NordiskOzempic$323$36,73818 claims
AstraZenecaFarxiga, Symbicort$876$29,54429 claims
Johnson & JohnsonXarelto$217$25,03920 claims
Boehringer IngelheimJardiance$14$10,11613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →